ProPhase Labs (NASDAQ:PRPH) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a research note issued to investors on Thursday. The firm issued a sell rating on the stock.

ProPhase Labs Stock Performance

Shares of NASDAQ PRPH opened at $0.49 on Thursday. The stock has a market cap of $11.70 million, a price-to-earnings ratio of -0.39 and a beta of -0.30. ProPhase Labs has a 12 month low of $0.46 and a 12 month high of $7.48. The company has a 50 day simple moving average of $0.69 and a two-hundred day simple moving average of $1.89. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 0.48.

Institutional Investors Weigh In On ProPhase Labs

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in shares of ProPhase Labs by 9.2% in the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock worth $389,000 after buying an additional 13,590 shares during the last quarter. HighTower Advisors LLC lifted its holdings in ProPhase Labs by 18.3% in the third quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock valued at $434,000 after acquiring an additional 27,673 shares during the period. Finally, Sheets Smith Wealth Management purchased a new stake in ProPhase Labs in the 4th quarter worth approximately $158,000. 9.45% of the stock is owned by institutional investors and hedge funds.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.